Literature DB >> 28986290

Assessment of hepatic metabolism-dependent nephrotoxicity on an organs-on-a-chip microdevice.

Zhongyu Li1, Lei Jiang2, Yujuan Zhu3, Wentao Su2, Cong Xu3, Tingting Tao3, Yang Shi2, Jianhua Qin4.   

Abstract

Drug-induced nephrotoxicity is one of the most frequent adverse events in pharmacotherapy. It has resulted in numerous clinical trial failures and high drug development costs. The predictive capabilities of existing in vitro models are limited by their inability to recapitulate the complex process of drug metabolism at the multi-organ level in vivo. We present a novel integrated liver-kidney chip that allows the evaluation of drug-induced nephrotoxicity following liver metabolism in vitro. The liver-kidney chip consists of two polydimethylsiloxane layers with compartmentalized micro-channels separated by a porous membrane. Hepatic and renal cells were co-cultured in separate micro-chambers on a single chip. Ifosfamide and verapamil were used as model drugs, and their metabolites produced by hepatic metabolism were identified using mass spectrometry, respectively. The metabolites triggered significantly distinct nephrotoxic effects as assessed by cell viability, lactate dehydrogenase leakage and permeability of renal cells. This in vitro liver-kidney model facilitates the characterization of drug metabolism in the liver as well as the assessment of subsequent nephrotoxicity in a single assay. Obviously, this multi-organ platform is simple and scalable, and maybe widely applicable to the evaluation of drug metabolism and safety during the early phases of drug development.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug testing; Hepatic metabolism; Microfluidics; Nephrotoxicity; Organs-on-a-chip

Mesh:

Substances:

Year:  2017        PMID: 28986290     DOI: 10.1016/j.tiv.2017.10.005

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  7 in total

1.  Microphysiological Systems: Next Generation Systems for Assessing Toxicity and Therapeutic Effects of Nanomaterials.

Authors:  Nureddin Ashammakhi; Mohammad Ali Darabi; Betül Çelebi-Saltik; Rumeysa Tutar; Martin C Hartel; Junmin Lee; Saber Hussein; Marcus J Goudie; Mercedes Brianna Cornelius; Mehmet R Dokmeci; Ali Khademhosseini
Journal:  Small Methods       Date:  2019-11-11

Review 2.  Organ-on-a-Chip Platforms for Drug Screening and Delivery in Tumor Cells: A Systematic Review.

Authors:  Inês M Gonçalves; Violeta Carvalho; Raquel O Rodrigues; Diana Pinho; Senhorinha F C F Teixeira; Ana Moita; Takeshi Hori; Hirokazu Kaji; Rui Lima; Graça Minas
Journal:  Cancers (Basel)       Date:  2022-02-13       Impact factor: 6.639

3.  An AC electrothermal self-circulating system with a minimalist process to construct a biomimetic liver lobule model for drug testing.

Authors:  Shengli Mi; Baihan Li; Xiaoman Yi; Yuanyuan Xu; Zhichang Du; Shuaitao Yang; Wei Li; Wei Sun
Journal:  RSC Adv       Date:  2018-11-01       Impact factor: 4.036

Review 4.  Application of Micro-Engineered Kidney, Liver, and Respiratory System Models to Accelerate Preclinical Drug Testing and Development.

Authors:  Hanieh Gholizadeh; Shaokoon Cheng; Agisilaos Kourmatzis; Hanwen Xing; Daniela Traini; Paul M Young; Hui Xin Ong
Journal:  Bioengineering (Basel)       Date:  2022-04-02

Review 5.  Engineering Organ-on-a-Chip to Accelerate Translational Research.

Authors:  Jihoon Ko; Dohyun Park; Somin Lee; Burcu Gumuscu; Noo Li Jeon
Journal:  Micromachines (Basel)       Date:  2022-07-28       Impact factor: 3.523

Review 6.  Human-induced pluripotent stem cell-derived cardiomyocytes, 3D cardiac structures, and heart-on-a-chip as tools for drug research.

Authors:  Kalina Andrysiak; Jacek Stępniewski; Józef Dulak
Journal:  Pflugers Arch       Date:  2021-02-24       Impact factor: 3.657

Review 7.  The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development.

Authors:  Paul A Walker; Stephanie Ryder; Andrea Lavado; Clive Dilworth; Robert J Riley
Journal:  Arch Toxicol       Date:  2020-05-06       Impact factor: 5.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.